Justin Kim

Justin Kim

Auto-generated profile, based on publicly available information

Justin Kim

School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, United States

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
VSVikram Vijay Shende
Vikram Vijay Shende
YKYogan Khatri
Yogan Khatri
SNSean A. Newmister
Sean A. Newmister
JSJacob N. Sanders
Jacob N. Sanders
PLPetra Lindovska
Petra Lindovska
DSDavid Sherman
David Sherman

29 March 2021 in ACS Central Science
Verified
Journal Article
Open access
DKDahye Kang
Dahye Kang
SCSheldon T. Cheung
Sheldon T. Cheung
AWAndrew Wong-Rolle
Andrew Wong-Rolle
JKJustin Kim
Justin Kim
Tumor hypoxia induces the large-scale adaptive reprogramming of cancer cells, promoting their transformation into highly invasive and metastatic species that lead to highly negative prognoses for cancer patients. We describe the synthesis and application of a hypoxia-responsive trigger derived from previously inaccessible enamine N-oxide structures. Hypoxia-dependent reduction of this motif by hemeproteins results in the concomitant activation of a caged molecule and a latent electrophile. We exploit the former in a hypoxia-activated prodrug application using a caged staurosporine molecule as a proof-of-principle. We demonstrate the latter in in vivo tumor labeling applications with enamine-N-oxide-modified near-infrared probes. Hypoxia-activated prodrug development has long been complicated by the heterogeneity of tumor hypoxia in patients. The dual drug release and imaging modalities of the highly versatile enamine N-oxide motif present an attractive opportunity for theranostic development that can address the need not only for new therapeutics but paired methods for patient stratification.

15 June 2022 in Chem
Verified
Journal Article
Closed access
DKDahye Kang
Dahye Kang
SLSanghyeon Lee
Sanghyeon Lee
JKJustin Kim
Justin Kim

8 April 2021 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
DKDahye Kang
Dahye Kang
JKJustin Kim
Justin Kim

10 July 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
JHJun Jacob Hu
Jun Jacob Hu
XLXing Liu
Xing Liu
JZJingxia Zhao
Jingxia Zhao
SXShiyu Xia
Shiyu Xia
JRJianbin Ruan
Jianbin Ruan
HWHao Wu
Hao Wu
Inflammasomes are multi-protein signalling scaffolds that assemble in response to invasive pathogens and sterile danger signals to activate inflammatory caspases (1/4/5/11), which trigger inflammatory death (pyroptosis) and processing and release of pro-inflammatory cytokines 1,2 . Inflammasome activation contributes to many human diseases, including inflammatory bowel disease, gout, type II diabetes, cardiovascular disease, Alzheimer’s disease, and sepsis, the often fatal response to systemic infection 3–6 . The recent identification of the pore-forming protein gasdermin D (GSDMD) as the final pyroptosis executioner downstream of inflammasome activation presents an attractive drug target for these diseases 7–11 . Here we show that disulfiram, a drug used to treat alcohol addiction 12 , and Bay 11-7082, a previously identified NF-κB inhibitor 13 , potently inhibit GSDMD pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Moreover, disulfiram, administered at a clinically well-tolerated dose, inhibits LPS-induced septic death and IL-1β secretion in mice. Both compounds covalently modify a conserved Cys (Cys191 in human and Cys192 in mouse GSDMD) that is critical for pore formation 8,14 . Inflammatory caspases employ Cys active sites, and many previously identified inhibitors of inflammatory mediators, including those against NLRP3 and NF-κB, covalently modify reactive cysteine residues 15 . Since NLRP3 and noncanonical inflammasome activation are amplified by cellular oxidative stress 16–22 , these redox-sensitive reactive cysteine residues may regulate inflammation endogenously, and compounds that covalently modify reactive cysteines may inhibit inflammation by acting at multiple steps. Indeed, both disulfiram and Bay 11-7082 also directly inhibit inflammatory caspases and pleiotropically suppress multiple processes in inflammation triggered by both canonical and noncanonical inflammasomes, including priming, puncta formation and caspase activation. Hence, cysteine-reactive compounds, despite their lack of specificity, may be attractive agents for reducing inflammation.

24 June 2021 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
DKDahye Kang
Dahye Kang
SCSheldon T. Cheung
Sheldon T. Cheung
JKJustin Kim
Justin Kim